Maria E Cabanillas1, Mimi I Hu, Camilo Jimenez. 1. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030.
Abstract
CONTEXT: Medullary thyroid cancer (MTC) is a rare form of thyroid cancer comprising approximately 4% of all thyroid cancers. The majority of patients have a relatively good prognosis; however, a subgroup of patients will require systemic therapy. Large phase III randomized trials led to the approval of two drugs--vandetanib and cabozantinib--for progressive or symptomatic MTC. The decision regarding which drug to initiate first is not entirely clear and is a common concern amongst treating physicians. EVIDENCE ACQUISITION AND SYNTHESIS: A review of the literature in English was conducted, and data were summarized and integrated into a decision matrix. CONCLUSIONS: The decision regarding which drug to initiate first for progressive MTC should be based on a careful review of the medical history, physical examination findings, medication list, electrocardiogram, laboratory results, and tumor characteristics. It is necessary to consider the relative contraindications when choosing which drug to initiate first.
CONTEXT: Medullary thyroid cancer (MTC) is a rare form of thyroid cancer comprising approximately 4% of all thyroid cancers. The majority of patients have a relatively good prognosis; however, a subgroup of patients will require systemic therapy. Large phase III randomized trials led to the approval of two drugs--vandetanib and cabozantinib--for progressive or symptomatic MTC. The decision regarding which drug to initiate first is not entirely clear and is a common concern amongst treating physicians. EVIDENCE ACQUISITION AND SYNTHESIS: A review of the literature in English was conducted, and data were summarized and integrated into a decision matrix. CONCLUSIONS: The decision regarding which drug to initiate first for progressive MTC should be based on a careful review of the medical history, physical examination findings, medication list, electrocardiogram, laboratory results, and tumor characteristics. It is necessary to consider the relative contraindications when choosing which drug to initiate first.
Authors: Johannes A A Meijer; Saskia le Cessie; Wilbert B van den Hout; Job Kievit; Johannes W Schoones; Johannes A Romijn; Johannes W A Smit Journal: Clin Endocrinol (Oxf) Date: 2009-06-26 Impact factor: 3.478
Authors: Maria E Cabanillas; Steven G Waguespack; Yulia Bronstein; Michelle D Williams; Lei Feng; Mike Hernandez; Adriana Lopez; Steven I Sherman; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2010-04-14 Impact factor: 5.958
Authors: J Fromigué; T De Baere; E Baudin; C Dromain; S Leboulleux; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2006-04-11 Impact factor: 5.958
Authors: Sarah Y Boostrom; Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Tanya L Hoskin; Ian D Hay Journal: Arch Surg Date: 2009-07
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Aubrey A Carhill; Maria E Cabanillas; Camilo Jimenez; Steven G Waguespack; Mouhammed A Habra; Mimi Hu; Anita Ying; Rena Vassilopoulou-Sellin; Robert F Gagel; Steven I Sherman; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2012-11-26 Impact factor: 5.958
Authors: A A Nella; M B Lodish; E Fox; F M Balis; M M Quezado; P O Whitcomb; J Derdak; E Kebebew; B C Widemann; C A Stratakis Journal: J Clin Endocrinol Metab Date: 2014-03-11 Impact factor: 5.958
Authors: Ramona Dadu; Mimi I Hu; Charles Cleeland; Naifa L Busaidy; Mouhammed Habra; Steven G Waguespack; Steven I Sherman; Anita Ying; Patricia Fox; Maria E Cabanillas Journal: Thyroid Date: 2015-08-20 Impact factor: 6.568